Shanghai Pharmaceuticals Holding Co (SHPMF) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sph9788 | Healthy Participants | Phase I | Recruiting | A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects. | Feb 18, 2025 | ― |
| Sph7485 | Advanced Solid Tumor | Phase I | Recruiting | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. | Jun 27, 2024 | ― |
| Sph7854 | Inflammatory Bowel Disease | earlyPhase1 | Recruiting | A Clinical Study of SPH7854 Granules in Healthy Subjects. | Jun 24, 2024 | ― |
| B007, Cyclosporin Capsules | Primary Membranous Nephropathy | phase2AndPhase3 | Recruiting | A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. | Jun 17, 2024 | ― |
| B007 | Generalized Myasthenia Gravis | phase2AndPhase3 | Recruiting | A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | Jun 03, 2024 | ― |
| Paclitaxel, B013 | Platinum-Resistant Recurrent Ovarian Cancer | Phase II | Recruiting | A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | May 23, 2024 | ― |
| Sph5030 | Biliary Tract Or Colorectal Cancer With Her2-Positive/Mutated | Phase II | Recruiting | A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | May 23, 2024 | ― |
| B001 | Neuromyelitis Optica Spectrum Disorders | phase2AndPhase3 | Recruiting | A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) | May 09, 2024 | ― |
| T3011 High Dose, T3011 Middle Dose, T3011 Low Dose | Advanced Solid Tumors | phase1AndPhase2 | Recruiting | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Jan 09, 2024 | ― |
| T3011 | Advanced Melanoma | phase1AndPhase2 | Recruiting | A Clinical Study of T3011 in Subjects With Advanced Melanoma | Jan 09, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sph9788 | Phase I | Healthy Participants | Recruiting | A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects. | Feb 18, 2025 | ― |
| Sph7485 | Phase I | Advanced Solid Tumor | Recruiting | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. | Jun 27, 2024 | ― |
| Sph7854 | earlyPhase1 | Inflammatory Bowel Disease | Recruiting | A Clinical Study of SPH7854 Granules in Healthy Subjects. | Jun 24, 2024 | ― |
| B007, Cyclosporin Capsules | phase2AndPhase3 | Primary Membranous Nephropathy | Recruiting | A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. | Jun 17, 2024 | ― |
| B007 | phase2AndPhase3 | Generalized Myasthenia Gravis | Recruiting | A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | Jun 03, 2024 | ― |
| Paclitaxel, B013 | Phase II | Platinum-Resistant Recurrent Ovarian Cancer | Recruiting | A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | May 23, 2024 | ― |
| Sph5030 | Phase II | Biliary Tract Or Colorectal Cancer With Her2-Positive/Mutated | Recruiting | A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | May 23, 2024 | ― |
| B001 | phase2AndPhase3 | Neuromyelitis Optica Spectrum Disorders | Recruiting | A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) | May 09, 2024 | ― |
| T3011 High Dose, T3011 Middle Dose, T3011 Low Dose | phase1AndPhase2 | Advanced Solid Tumors | Recruiting | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | Jan 09, 2024 | ― |
| T3011 | phase1AndPhase2 | Advanced Melanoma | Recruiting | A Clinical Study of T3011 in Subjects With Advanced Melanoma | Jan 09, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Shanghai Pharmaceuticals Holding Co Class H (SHPMF) have in its pipeline
Shanghai Pharmaceuticals Holding Co SHPMF is currently developing the following drugs: Sph9788, Sph7485, Sph7854, B007, Cyclosporin Capsules, B007, Paclitaxel, B013, Sph5030, B001, T3011 High Dose, T3011 Middle Dose, T3011 Low Dose, T3011, Sph4336, Cadonilimab, Sph4336 Tablets, Sph3127 Tablets With Dose A, Sph3127 Tablets With Dose B, Sph4336 Tablets 400Mg, Lt3001 Drug:High Dose, Lt3001 Drug:Low Dose, B013+Nab-Paclitaxel, Sph5030 Tablets, B001 Injection, Tk216+Vincristin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.